Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. developed cell therapies and immunotherapies for cancer and other incurable diseases, with company news centered on anitocabtagene autoleucel, or anito-cel, an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Coverage included clinical data from the iMMagine program, scientific presentations on the D-Domain binder, and collaboration activity with Kite, a Gilead company.
Arcellx became a wholly owned subsidiary of Gilead Sciences after the completed acquisition in 2026, and its common stock was delisted from the Nasdaq Global Select Market. Later company developments therefore include the completed transaction, shareholder-related deal coverage, capital-structure matters, and public-company status changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm specializing in immunotherapies for cancer and other severe diseases, will participate in the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. This session will be a fireside chat featuring company management.
A live webcast will be available on Arcellx's website, and a replay will be accessible for 30 days post-event. Arcellx focuses on innovative cell therapies, including its lead candidate, CART-ddBCMA, targeting relapsed or refractory multiple myeloma, currently in a Phase 2 trial. The FDA has granted it several designations, including Fast Track and Orphan Drug.
Arcellx, Inc. (NASDAQ: ACLX) reported significant business highlights and financial results for Q4 and the year ended December 31, 2022. The company signed a strategic collaboration with Kite to co-develop CART-ddBCMA for multiple myeloma, receiving $225 million upfront and a $100 million equity investment. In clinical trials, CART-ddBCMA showed a 100% overall response rate in a Phase 1 trial. However, R&D expenses surged to $149.6 million for 2022 due to non-cash expenses and increased headcount. Arcellx ended 2022 with $254.8 million in cash, positioning it well for further pipeline development.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on innovative immunotherapies for cancer, announced participation in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 1:00 p.m. ET. A live webcast will be available on Arcellx's website in the Investors section, with a replay accessible for 30 days. Arcellx is advancing its lead candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma and is also developing the dosable CAR-T therapy, ARC-SparX. The company holds multiple FDA designations for its therapies, reinforcing its commitment to advancing cell therapy.